5th May 2015 06:57
LONDON (Alliance News) - Premaitha Health PLC said Tuesday it has filed a defence and counter-claim in connection with a patent infringement case brought against it by Illumina Inc over its non-invasive prenatal test IONA.
Illumina filed a case against Premaitha Health in March over two patents licensed to Illumina by Sequenom Inc covering the use of cell-free fetal DNA for non-invasive prental testing.
"We have looked at the legal position very carefully and, in our view, the claims are without substance," said Premaitha Chief Executive Officer Stephen Little in a statement.
"Within the UK and globally, it is vitally important that both expectant mothers and health care authorities have the freedom to make appropriate and informed choices. We believe our best-in-class IONA test enables this choice to be made," Little added.
The company won a three-year contract to provide the test to St George's University Hospitals NHS Foundation Trust in March. The test uses a sample of maternal blood to estimate the risk of a foetus having serious genetic disorders.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Premaitha Health